Today: 9 June 2026
Browse Category

EPA:BNP 27 June 2025 - 31 March 2026

Oil price forecast 2026: Brent eyed near $55 early as supply glut tests OPEC+ resolve

Oil price forecast 2026: Brent eyed near $55 early as supply glut tests OPEC+ resolve

Brent crude ended 2025 at $60.85 a barrel, down 19% for the year, with analysts forecasting a dip to $55 in early 2026 as supply outpaces demand. The International Energy Agency projects a 2026 surplus of up to 3.84 million barrels per day. OPEC+ paused output hikes for the first quarter. Traders await the group’s January 4 meeting for signals on possible production cuts.
1 January 2026
··
Bank Stocks Week Ahead: Fed “Pause” Signals, Holiday-Thin Trading, and Buybacks Put Financials in Focus (Dec. 22–26, 2025)

Bank Stocks Week Ahead: Fed “Pause” Signals, Holiday-Thin Trading, and Buybacks Put Financials in Focus (Dec. 22–26, 2025)

Federal Reserve officials signaled no urgency for further rate cuts, with New York Fed President John Williams and Cleveland Fed President Beth Hammack both emphasizing a steady approach. Key U.S. economic data delayed by a government shutdown will be released during a shortened Christmas trading week, increasing uncertainty for bank stocks. Markets will close Dec. 25; volatility may rise due to thin liquidity.
21 December 2025
··············
France Stock Market Today, 24 November 2025: CAC 40 Closes Near 7,960 as Defence Stocks Fall and Buybacks Dominate

France Stock Market Today, 24 November 2025: CAC 40 Closes Near 7,960 as Defence Stocks Fall and Buybacks Dominate

The CAC 40 closed down 0.29% at 7,959.67 on Monday, slipping below the 8,000 mark after swinging between 7,958.61 and 8,033.38. Defence stocks Safran and Thales fell sharply on Ukraine peace-talk headlines, while autos and banks resisted the sell-off. The broader SBF 120 index also edged lower. Market volatility remained elevated, with the CAC 40 VIX just below 19.
25 November 2025
··
Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Paris Stocks Climb as CAC 40 Nears Record; Edenred Sinks on Brazil Fee CapFrance’s blue‑chip index extends gains; luxury and banks advance while meal‑voucher giant tumbles after Brasília’s decree

The CAC 40 rose about 1% to 8,240 in early Paris trading Wednesday, nearing its October record high. Edenred shares dropped 9% after Brazil capped merchant fees and sped up voucher settlements, hitting earnings prospects. Gains were led by luxury and financial stocks, while STMicroelectronics and Dassault Systèmes edged lower. France’s annual inflation slowed to 1.0% in October, with ECB rates unchanged.
12 November 2025
······
Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

CAC 40 Near Record High, Defies Moody’s Warning as Luxury Stocks Rally

France’s CAC 40 index held near 8,230 points Monday, flat and just below last week’s record. Moody’s cut France’s outlook to “negative,” but markets were unmoved. Kering surged 9% last week after better-than-feared sales, while Dassault Systèmes and STMicroelectronics dropped over 13% on weak guidance. The CAC 40 is up about 10% year-to-date.
27 October 2025
········
Latest Fintech and Digital Finance Trends (June 27th, 2025)

Latest Fintech and Digital Finance Trends (June 27th, 2025)

Q1 2025 fintech funding rose 18% to over $10 billion, the highest in two years. FedNow processed 1.3 million transactions, up 43% quarter-over-quarter, with over 1,200 banks onboarded. The European Payments Initiative launched cross-border instant payments with Wero, now at 40 million users. Xero agreed to buy Melio for $2.5 billion; Shift4 will acquire Smartpay for $180 million.
27 June 2025
······

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop